Here, Mark Dickman, Professor in Bioanalytical Science and Engineering at the University of Sheffield, explores how analytical techniques such as liquid chromatography-mass spectrometry can support the manufacturing of mRNA therapeutics.
Large RNA is rapidly emerging as a new class of therapeutics. Nowhere is this more publicly evident than in the development, regulatory approval, and efficacious use of mRNA‑based vaccines for COVID-19. Beyond the high-profile COVID-19 vaccines, mRNA therapeutics are crucial in applications such as protein replacement therapies and regenerative medicine. Scaling up the production of mRNA therapeutics to meet today’s growing demand requires improved optimisation of the associated analytics. An automated liquid chromatography‑mass spectrometry (LC-MS) workflow used in conjunction with RNase mass mapping is proving successful in simplifying and accelerating mRNA analysis.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
mRNA therapeutics and their manufacture
mRNA therapeutics contain a specific sequence (coding sequence), which corresponds to the gene or protein of interest. The mRNA is packaged and delivered to the cytoplasm of host cells, where it is translated into a protein that exerts the desired cellular effect. This mRNA is formulated within a delivery vehicle, usually lipid nanoparticles, and once inside the target cell, it “hijacks” the cellular machinery to make the desired protein.
Manufacturing mRNA for therapeutic use involves in vitro transcription (IVT). This enzymatic process employs a DNA template, typically plasmid DNA, which carries the mRNA sequence of interest. After the DNA template is linearised, the addition of T7 RNA polymerase and nucleoside triphosphate (NTP) building blocks enable enzymatic production of the mRNA containing the required protein-coding sequence.
While the manufacturing process is relatively simple, it results in the generation of numerous contaminants and unwanted by-products. These include T7 RNA polymerase, NTPs, plasmid DNA, double-stranded RNA (dsRNA), failure sequences, degradation products, incomplete capping and polyadenylated products. All present a significant challenge from an analytical perspective for the downstream purification and analysis of mRNA therapeutics.
The urgent need for improved analytics
Current analytical methods for characterising RNA therapeutics are limited and the development of strategies for large RNA (typically >1000 nucleotides), including mRNA vaccines, has proven especially challenging – from the separation processes involved to analysis of degradation products. Consequently, there is a need for faster, more robust, and higher-resolution analytics since these are critical for successful manufacturing development.
Global demand for vaccines is growing and there is increasing pressure to scale up production. Process optimisation depends on good analytics, which are essential to ensure consistent batch‑to-batch manufacturing, process repeatability, and quality of the mRNA produced. Monitoring critical quality attributes (CQAs) such as identity, contaminants, yield, and potential modifications is vital. Validated analytical methods also have a fundamental role in supporting clinical development and regulatory submissions.
RNase mass mapping and its challenges
Mass spectrometry (MS)-based methods offer a powerful approach for RNA analysis. MS-based RNase mapping methods have proven successful in various applications, including sequence mapping and identifying post-transcriptional modifications. Recent work applying this technology to large RNA has driven the development of a rapid automated method for direct characterisation and comprehensive sequence mapping of mRNA therapeutics.
Following the purification of the resulting mRNA, ion-pair reversed-phase high-performance liquid chromatography (IP-RP-HPLC) provides data on yield, quantity, and quality, but offers no sequencing information. Alternative tools are therefore needed for further analysis, and it is here that mass mapping is being applied.
RNase mass mapping is similar to protein and peptide mass fingerprinting. It involves digesting the mRNA of interest with a specific RNase (eg, RNase A or T1) to generate a series of oligonucleotides.”
RNase mass mapping is similar to protein and peptide mass fingerprinting. It involves digesting the mRNA of interest with a specific RNase (eg, RNase A or T1) to generate a series of oligonucleotides. Mass spectrometry, incorporating high mass accuracy and tandem MS analysis, is then applied to sequence the fragments.
This mapping technique is already being used to analyse RNA in processes such as CRISPR1 but applying it to much larger mRNA therapeutics is less straightforward. The smaller RNA molecules (~100 nucleotides) involved in CRISPR produce a limited number of different sequences following RNase digestion, making analysis simple. Conversely, mRNA therapeutics are thousands of nucleotides in length. Using high-frequency RNases, such as RNase A or T1, to digest them produces many identical short oligonucleotide sequences that map to multiple points on the mRNA.
Another significant issue has been the lack of robust software for oligonucleotide characterisation. Manual data interpretation is often used but not only is this laborious and time consuming, it also restricts experimental scope and limits both productivity and confidence in the results, especially where very large numbers of fragments are generated. A different approach is essential to overcome the challenges of mapping large RNA.
Implementing an effective automated workflow
The newly developed workflow2 involves the partial digestion of the mRNA therapeutic using RNase T1 immobilised on magnetic beads. This is followed by purification, sequencing, and automated data analysis.
Compared with standard RNase digestion processes, the controlled partial digestion using immobilised enzyme generates increased numbers of larger sized fragments. Unlike the smaller fragments resulting from a standard digestion of mRNA, these larger fragments have unique sequences that map to specific points on the mRNA molecule. Enzyme immobilisation also avoids RNase contamination of the chromatography column used in the separation step, thus preventing any further digestion.
High-resolution separation of the oligonucleotide fragments is critical to the success of subsequent analysis. In this workflow, separation is achieved in around 40 minutes with IP-RP-HPLC using triethylamine (TEA) in combination with hexafluoroisopropanol (HFIP) and an acetonitrile gradient during the elution. This typically results in sharp elution peaks and length‑based separation of a large number of oligonucleotide fragments.
MS analysis of the mRNA digest requires high-resolution accurate-mass (HRAM) capabilities.2 Following the application of MS, the final, and crucial, step of the workflow is the automated data analysis. The software used here enables automated identification of the oligonucleotide fragments and supports specific RNase mass mapping approaches, as illustrated in Figure 1. Its sequence manager allows the input of the sequence of interest together with any modifications.
Figure 1: Automating data analysis.
The RNase mass mapping tool then generates a theoretical in silico digest and identifies oligonucleotide fragments based on the intact mass from high‑resolution MS1 spectra and the nucleic acid sequence and modifications from the MS2 spectra. The output chromatogram highlights the identified oligonucleotides on the RNA. This is then converted to a sequence map showing all the sequences identified and their locations on the mRNA sequence of interest.
Applying the workflow to mRNA therapeutics
Applying the developed workflow to mRNA therapeutics [SARS-CoV-2 spike protein mRNA and enhanced green fluorescent protein (eGFP) mRNA] confirmed that immobilising RNase T1 on magnetic beads gave tight control of the digestion process, generating highly reproducible partial T1 digests and separations. With respect to sequence mapping, Figure 2 shows the sequence coverage data in experiments performed using partial RNase T1 digests and traditional complete RNase T1 digests for both SARS-CoV-2 spike protein mRNA and eGFP mRNA. Using partial digests, approximately 85 percent sequence coverage was achieved. In contrast, complete RNase T1 digests gave many non-unique fragments, resulting in only 10-25 percent sequence coverage. As a control against false positive identifications, a random sequence of the same size and same GC content as the target mRNAs was included in all experiments. Searching the MS data against this random sequence gave extremely low sequence coverage, confirming the quality of the data.
Figure 2: Sequence mapping of mRNA therapeutics.
Building confidence in results
Also important is the ability of the software to identify different sequence isomers. Even using the partial digestion strategy, several isobaric oligonucleotides with the same nucleic acid composition can be generated, each of which corresponds to a different sequence. Differential separation using IP-RP‑HPLC in conjunction with the tandem MS, followed by automated software analysis, enables clear identification of the different sequences.
Further confidence in sequence identification is gained from IP-RP-HPLC conditions generating several different charge states for each oligonucleotide fraction. Tandem MS then delivers sequence information on each of these oligonucleotide fractions.
A method fit for purpose
Mass spectrometry techniques are widely used for RNA analysis. Unfortunately, the large molecular size of mRNA presents challenges in methods such as RNase mass mapping, where the use of high frequency RNases fails to generate unique sequences for analysis. Reliable characterisation is, however, critical to successful manufacturing scale-up for the growing body of mRNA therapeutics in production and in the pipeline. New approaches are therefore needed.
Mass spectrometry techniques are widely used for RNA analysis.”
The LC-MS workflow described delivers high-quality results while simplifying and automating the process. It uses RNase T1 immobilised on magnetic beads to achieve a controlled partial digestion of the mRNA. This results in fragments that are larger and unique in sequence than those generated using standard RNase mapping methods. The partial digest is separated by IP‑RP-HPLC and analysed by HRAM MS. The data is automatically processed to generate high confidence identification of oligonucleotide fragments and comprehensive mRNA sequence mapping, which avoids the need for laborious manual interpretations and gives high confidence in the results.
Overall, the new workflow delivers rapid characterisation of mRNA therapeutics. It provides the information needed for identity testing, sequence validation, and analysis of impurities, essential for successful manufacturing and scale-up.
About the author
Dr Mark J Dickman, PhD is currently a Professor in Bioanalytical Science and Engineering in the Department of Chemical and Biological Engineering at the University of Sheffield. He obtained a first-class honours degree in biochemistry/chemistry at the University of Sheffield. Mark continued at the Krebs Institute, where he obtained his PhD. Later, he joined a biotechnology company, Transgenomic Ltd, where he worked as a research scientist developing analytical techniques, including DNA/RNA chromatography.
References
1. Tamulaitis G, Kazlauskiene M, Manakova E, et al. Programmable RNA shredding by the type III-A CRISPR-Cas system of Streptococcus thermophilus. Mol Cell. 2014 Nov 20; 56(4), 506‑17. https://pubmed.ncbi.nlm.nih.gov/25458845/
2. Vanhinsbergh CJ, Criscuolo A, Sutton JN, et al. Characterization and Sequence Mapping of Large RNA and mRNA Therapeutics Using Mass Spectrometry. Anal. Chem. 2022; 94 (20), 7339-7349 https://pubs.acs.org/doi/10.1021/acs.analchem.2c00765
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.